Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Triple Negative Breast Neoplasms 14Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Breast Neoplasms, Male 5Brain Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3HER2-positive Advanced Breast Cancer 3Advanced Breast Cancer 3Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Lung Neoplasms 2HER2-negative Breast Cancer 2HER2 Positive Breast Cancer 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Recurrence 1Primary Breast Cancer 1Pheochromocytoma 1Patient Acceptance of Health Care 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Metastatic HER2-positive Breast Cancer 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Inflammatory Breast Neoplasms 1Hormone Receptor Positive Advanced Breast Cancer 1

Interventions

apatinib 1Vinorelbine 1Injections 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Triple-Negative Breast Cancer × Vinorelbine × Breast × Clear all
NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Fudan University

Phase 2 Completed
66 enrolled
Breast

Advanced Triple-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡